Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Indukala Doddamane

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Cancers|November 12, 2013
Targeted radionuclide therapyDevrim Ersahin, Indukala Doddamane, David Cheng
Current Opinion in Oncology|October 22, 2009
Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer managementMing-Kai Chen, Indukala Doddamane, David W Cheng
Thyroid : Official Journal of the American Thyroid Association|February 4, 2012
The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancerMing-Kai Chen, Mona Yasrebi, Jason Samii, et al.
American Journal of Clinical Oncology|August 22, 2014
Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal AdenocarcinomaJia Li, Xiaopan Yao, Jeremy S Kortmansky, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 3, 2007
Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levelsSeng C Ong, Heiko Schöder, Snehal G Patel, et al.
Cancer|February 5, 2015
Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumorsMaysa M Abu-Khalaf, Megan A Baumgart, Scott N Gettinger, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Cancers|November 12, 2013
Targeted radionuclide therapyDevrim Ersahin, Indukala Doddamane, David Cheng
Current Opinion in Oncology|October 22, 2009
Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer managementMing-Kai Chen, Indukala Doddamane, David W Cheng
Thyroid : Official Journal of the American Thyroid Association|February 4, 2012
The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancerMing-Kai Chen, Mona Yasrebi, Jason Samii, et al.
American Journal of Clinical Oncology|August 22, 2014
Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal AdenocarcinomaJia Li, Xiaopan Yao, Jeremy S Kortmansky, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 3, 2007
Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levelsSeng C Ong, Heiko Schöder, Snehal G Patel, et al.
Cancer|February 5, 2015
Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumorsMaysa M Abu-Khalaf, Megan A Baumgart, Scott N Gettinger, et al.
Pageof 1